Form 8-K - Current report:
SEC Accession No. 0000950170-24-095687
Filing Date
2024-08-13
Accepted
2024-08-12 21:04:54
Documents
13
Period of Report
2024-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gyre-20240813.htm   iXBRL 8-K 45886
2 EX-99.1 gyre-ex99_1.htm EX-99.1 341925
3 GRAPHIC img51893664_0.jpg GRAPHIC 12034
  Complete submission text file 0000950170-24-095687.txt   539316

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT gyre-20240813.xsd EX-101.SCH 25991
16 EXTRACTED XBRL INSTANCE DOCUMENT gyre-20240813_htm.xml XML 4684
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 241198462
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)